卡维地洛
药效学
药物遗传学
CYP2D6型
药理学
药代动力学
医学
内科学
生物
基因型
遗传学
细胞色素P450
心力衰竭
新陈代谢
基因
作者
Daniel B. Sehrt,Ingolf Meineke,Mladen Vassilev Tzvetkov,Şenol Gültepe,Jürgen Brockmöller
出处
期刊:Pharmacogenomics
[Future Medicine]
日期:2011-05-23
卷期号:12 (6): 783-795
被引量:63
摘要
AIMS: Carvedilol is an effective treatment in hypertension and chronic heart failure. The medical impact of polymorphisms in CYP2D6 and in the β-adrenergic receptors ADRB1 and ADRB2 on the pharmacokinetics and pharmacodynamics of carvedilol is controversial. METHODS: After carvedilol 25 mg was administered to 110 volunteers, concentrations were enantioselectively quantified and effects on resting and exercise-induced heart rate and blood pressure were analyzed using population pharmacokinetic, pharmacodynamic and pharmacogenetic modeling. RESULTS: There were significant CYP2D6 allele-specific differences in carvedilol pharmacokinetics, but the CYP2D6 genotype had no effect on heart rate, blood pressure or adverse effects. ADRB1 Gly49 was associated with higher baseline heart rates and with greater carvedilol effects on exercise heart rates. Carriers of ADRB2 Gln27 had greater reduction in resting blood pressure by carvedilol compared with Glu27. CONCLUSION: Carvedilol is a drug where CYP2D6-related pharmacokinetic variation is apparently not carried forward into pharmacodynamic variation. Although current knowledge does not allow utilizing ADRB1 and ADRB2 genotypes for clinical treatment decisions, our data should stimulate further research on the impact of these genotypes in health and disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI